X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (30) 30
animals (28) 28
mice (23) 23
obesity (19) 19
insulin resistance (17) 17
male (14) 14
article (13) 13
cell biology (12) 12
metabolism (12) 12
inflammation (11) 11
humans (10) 10
mice, inbred c57bl (10) 10
mice, knockout (10) 10
biochemistry & molecular biology (9) 9
endocrinology & metabolism (9) 9
fibroblast growth factors - pharmacology (9) 9
glucose (9) 9
insulin (9) 9
physiological aspects (9) 9
rodents (9) 9
adipose-tissue (8) 8
body weight (8) 8
macrophages (8) 8
energy-expenditure (7) 7
fibroblast growth factors (7) 7
liver (7) 7
liver - metabolism (7) 7
obesity - metabolism (7) 7
resistance (7) 7
type 2 diabetes (7) 7
glucose - metabolism (6) 6
insulin sensitivity (6) 6
mice, obese (6) 6
molecular biology (6) 6
physiology (6) 6
research article (6) 6
abridged index medicus (5) 5
adiponectin (5) 5
antibodies, monoclonal, humanized - pharmacology (5) 5
dextrose (5) 5
diabetes (5) 5
diabetes mellitus (5) 5
fgf21 (5) 5
fibroblast growth factors - therapeutic use (5) 5
glucose metabolism (5) 5
growth (5) 5
medicine, research & experimental (5) 5
multidisciplinary sciences (5) 5
obesity - drug therapy (5) 5
activation (4) 4
adipose tissue - metabolism (4) 4
antibodies, monoclonal, humanized - therapeutic use (4) 4
beta-klotho (4) 4
body weight - drug effects (4) 4
cells (4) 4
female (4) 4
fibroblast growth factor (4) 4
homeostasis (4) 4
hypoglycemic agents - pharmacology (4) 4
medicine (4) 4
middle aged (4) 4
obesity - complications (4) 4
proto-oncogene proteins c-akt - metabolism (4) 4
rats (4) 4
research (4) 4
science (4) 4
signal transduction (4) 4
t-cells (4) 4
acetyl-coa carboxylase - metabolism (3) 3
adipocytes - metabolism (3) 3
adipose tissues (3) 3
analysis (3) 3
animal models (3) 3
anti-obesity agents - therapeutic use (3) 3
antibodies, monoclonal, humanized - administration & dosage (3) 3
antibodies, monoclonal, humanized - pharmacokinetics (3) 3
biochemistry, genetics and molecular biology (3) 3
brain (3) 3
cells, cultured (3) 3
diabetes mellitus, type 2 - drug therapy (3) 3
diet (3) 3
diet, high-fat (3) 3
disease models, animal (3) 3
dose-response relationship, drug (3) 3
energy metabolism - drug effects (3) 3
energy metabolism - physiology (3) 3
expression (3) 3
fibroblast growth factors - administration & dosage (3) 3
fibroblast growth factors - metabolism (3) 3
fibroblast growth factors - pharmacokinetics (3) 3
fibroblasts (3) 3
glucose tolerance (3) 3
glucose tolerance test (3) 3
hepatocytes - metabolism (3) 3
hormones, hormone substitutes, and hormone antagonists (3) 3
inflammation - immunology (3) 3
inflammation - metabolism (3) 3
insulin - pharmacology (3) 3
insulin receptor substrate proteins - metabolism (3) 3
insulin resistance - immunology (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Medicine, ISSN 1078-8956, 2015, Volume 21, Issue 3, pp. 239 - 247
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2015, Volume 10, Issue 3, pp. e0119104 - e0119104
Pharmacological administration of fibroblast growth factor 21 (FGF21) improves metabolic profile in preclinical species and humans. FGF21 exerts its metabolic... 
KLOTHO | BIOSYNTHESIS | MULTIDISCIPLINARY SCIENCES | INCREASES ENERGY-EXPENDITURE | GROWTH | TISSUES | INSULIN SENSITIVITY | BRAIN | Glucose Tolerance Test | Antibodies, Monoclonal, Humanized - therapeutic use | Obesity - drug therapy | Diet - adverse effects | Male | Fibroblast Growth Factors - pharmacology | Weight Loss - drug effects | Administration, Intravenous | Animals | Antibodies, Monoclonal, Humanized - administration & dosage | Fibroblast Growth Factors - pharmacokinetics | Time Factors | Antibodies, Monoclonal, Humanized - pharmacokinetics | Fibroblast Growth Factors - administration & dosage | Models, Biological | Antibodies, Monoclonal, Humanized - pharmacology | Injections, Subcutaneous | Mice, Obese | Blood Glucose - metabolism | Leptin - deficiency | Fibroblast Growth Factors - therapeutic use | Fibroblast growth factor | Animal models | Intravenous administration | Body weight | Homeostasis | Glucose | Metabolites | Rodents | Fibroblasts | Modelling | Growth factors | Half life | Obesity | Pharmacodynamics | Research & development--R&D | Radioactive half-life | Pharmacology | C-Terminus | Bioavailability | Glucose tolerance | Signaling | Weight control | Diet | Klotho protein | Leptin | N-Terminus | Weight reduction | Insulin resistance | Mice | In vivo methods and tests | Diabetes | Pharmacokinetics | Metabolic disorders | Index Medicus | Research & development | R&D
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 12/2017, Volume 19, Issue 12, pp. 1762 - 1772
Aims: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-05231023, a long-acting fibroblast growth factor 21 (FGF21) analogue, in... 
fibroblast growth factor 21 | blood pressure | 1 | heart rate | type 2 diabetes | bone biomarkers | IGF | IGF-1 | FATTY LIVER-DISEASE | ENERGY-EXPENDITURE | PF-05231023 | PROFILE | PHARMACOKINETICS | ENDOCRINOLOGY & METABOLISM | MICE | FGF21 | Hypertriglyceridemia - drug therapy | Fibroblast Growth Factors - adverse effects | Follow-Up Studies | Obesity - drug therapy | Species Specificity | Humans | Middle Aged | Half-Life | Anti-Obesity Agents - adverse effects | Male | Obesity - blood | Anti-Obesity Agents - therapeutic use | Bone Remodeling - drug effects | Delayed-Action Preparations - administration & dosage | Dose-Response Relationship, Drug | Anti-Obesity Agents - pharmacokinetics | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Fibroblast Growth Factors - administration & dosage | Hypertension - chemically induced | Delayed-Action Preparations - pharmacokinetics | Female | Drug Resistance | Fibroblast Growth Factors - therapeutic use | Body Mass Index | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Hypolipidemic Agents - adverse effects | Anti-Obesity Agents - administration & dosage | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Drug Administration Schedule | Obesity - complications | Biomarkers - blood | Hypertension - physiopathology | Hypertriglyceridemia - blood | Animals | Fibroblast Growth Factors - pharmacokinetics | Delayed-Action Preparations - adverse effects | Hypertriglyceridemia - complications | Hypolipidemic Agents - administration & dosage | Delayed-Action Preparations - therapeutic use | Hypolipidemic Agents - therapeutic use | Infusions, Intravenous | Hypolipidemic Agents - pharmacokinetics | Type 2 diabetes | Obesity | Heart beat | Blood cholesterol | Collagen | Analysis | Body weight | Primates | Fibroblast growth factors | Blood pressure | Fibroblast growth factor | Pharmacodynamics | Diabetes mellitus | Homeostasis | Lipids | Triglycerides | Body weight loss | Bone turnover | Monkeys & apes | Cholesterol | Adiponectin | Heart rate | Rodents | Fibroblasts | Atorvastatin | Lead | Safety | Pharmacokinetics | Growth factors | Diabetes mellitus (non-insulin dependent) | Lipoproteins (high density) | Index Medicus
Journal Article
Journal Article
Journal of Pharmacokinetics and Pharmacodynamics, ISSN 1567-567X, 8/2016, Volume 43, Issue 4, pp. 411 - 425
Journal Article
Journal Article
ASSAY and Drug Development Technologies, ISSN 1540-658X, 06/2008, Volume 6, Issue 3, p. 462
Journal Article
Journal Article